Article
Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group study.
Medical oncology (Northwood, London, England) - 1 Mar 2013
Tateishi Kazunari, Ichiyama Takashi, Hirai Kazuya, Agatsuma Toshihiko, Koyama Shigeru, Hachiya Tsutomu, Morozumi Nobutoshi, Shiina Takayuki, Koizumi Tomonobu
Abstract excerpt
The clinical efficacy and outcomes of gefitinib therapy as a first-line treatment for elderly patients with non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations were analyzed retrospectively. We analyzed chemotherapy-naïve NSCLC patients aged 75 years or older who had EGFR mutations (exon 19 deletion mutation or L858R), who were initially treated with gefitinib (250 mg) once...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.